Originally published by our sister publication Infectious Disease Special Edition
The first respiratory syncytial virus (RSV) vaccine, adjuvanted (Arexvy, GSK) has been approved for use in the United States by the FDA, according to an agency release.
The FDA approved the vaccine for the prevention of lower respiratory tract disease (LRTD) resulting from RSV in adults who are 60 years of age and older.
The circulation of RSV is seasonal, according to the FDA, and cases typically begin appearing